CardioDx raises $21 million in new funding
Augmenix, developer of hydrogel-based radiation oncology products, closes $10.8M in Series D fundraising
Allergan announces earnings and restructuring/layoffs, while still fighting Valeant
AbbVie and Shire - latest on the merger
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Teleflex Medical | 1 | 10 | 900 % |
| SIGA technologies | 1 | 6 | 500 % |
| Validus | 1 | 5 | 400 % |
| Questcor | 1 | 5 | 400 % |
| Azimuth | 1 | 4 | 300 % |
| Agilent | 7 | 27 | 286 % |
| Dragon Pharmaceutical | 2 | 7 | 250 % |
| Arena Pharmaceuticals | 1 | 3 | 200 % |
| Watson Pharmaceuticals | 1 | 3 | 200 % |
| Akamai | 3 | 9 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| ONYX Pharmaceuticals | 7 | 48 | 586 % |
| Advanced Bionics | 1 | 5 | 400 % |
| Discovery Labs | 6 | 27 | 350 % |
| Amag Pharmaceuticals | 2 | 9 | 350 % |
| Arrow International | 10 | 44 | 340 % |
| Abaxis | 10 | 41 | 310 % |
| Cytokinetics | 1 | 4 | 300 % |
| CombinatoRx | 1 | 4 | 300 % |
| AcelRx | 25 | 100 | 300 % |
| Cantel Medical | 1 | 4 | 300 % |